Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

BACKGROUND: Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing capacity of γδ T cells, which are critic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Niannian, Mukherjee, Neelam, Reyes, Ryan M, Gelfond, Jonathan, Javors, Martin, Meeks, Joshua J., McConkey, David J, Shu, Zhen-Ju, Ramamurthy, Chethan, Dennett, Ryan, Curiel, Tyler J, Svatek, Robert S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929866/
https://www.ncbi.nlm.nih.gov/pubmed/33653802
http://dx.doi.org/10.1136/jitc-2020-001941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929866/
https://www.ncbi.nlm.nih.gov/pubmed/33653802
http://dx.doi.org/10.1136/jitc-2020-001941

Ejemplares similares